PD-L1 tested non-small cell lung carcinoma tissue microarray, containing 20 cases of PD-L1(Sp263) is a negative or positive, single core per case. Pathology grade, TNM Classification, Clinical stage, and PD-L1(Sp263) information available.
- 20 cases of squamous cell carcinoma are negative
- 13 cases of squamous cell carcinoma
- 5 cases of adenocarcinoma
- 2 cases of adenosquamous carcinoma are positive
Price
$255.00
Catalogue No | LC401 |
Description | PD-L1 tested non-small cell lung carcinoma tissue microarray, containing 20 cases of PD-L1(Sp263) is a negative or positive, single core per case. Pathology grade, TNM Classification, Clinical stage, and PD-L1(Sp263) information available. |
Species | Human |
Fixative | Formalin |
Total Cases | 40 |
Total Cores | 40 |
Core Diameter | 1.5 mm |
Section Thickness | 5 µm |
Storage | Short term RT; Long term 4ºC |
Usage | For research use only. Designed for Immunohistochemistry (IHC) and In Situ Hybridization (ISH) |
A | LU | LU | LU | LU | LU | LU | LU | LU |
B | LU | LU | LU | LU | LU | LU | LU | LU |
C | LU | LU | LU | LU | LU | LU | LU | LU |
D | LU | LU | LU | LU | LU | LU | LU | LU |
E | LU | LU | LU | LU | LU | LU | LU | LU |
Showing All Data
No. | Map ID | Age | Sex | Organ | Pathology Diagnosis | Grade | TNM | Stage | Type | PL-L1(Sp263) |
---|---|---|---|---|---|---|---|---|---|---|
1 | A1 | 56 | M | Lung | Squamous cell carcinoma | 2 | T2N3M0 | IIIB | Malignant | TC≥25% |
2 | A2 | 70 | M | Lung | Squamous cell carcinoma | 2 | T2N0M0 | IB | Malignant | TC≥25% |
3 | A3 | 61 | M | Lung | Squamous cell carcinoma | 2 | T2N0M0 | IB | Malignant | TC=100% |
4 | A4 | 63 | M | Lung | Squamous cell carcinoma | 2 | T3N1M0 | IIIA | Malignant | TC≥85% |
5 | A5 | 64 | M | Lung | Squamous cell carcinoma | 2 | T2N1M0 | IIA | Malignant | TC≥25% |
6 | A6 | 58 | M | Lung | Squamous cell carcinoma | 2 | T2N0M0 | IB | Malignant | TC≥25% |
7 | A7 | 65 | M | Lung | Squamous cell carcinoma | 2 | T2N0M0 | IB | Malignant | TC=100% |
8 | A8 | 50 | M | Lung | Squamous cell carcinoma | 3 | T2N0M0 | IB | Malignant | TC≥25% |
9 | B1 | 56 | M | Lung | Squamous cell carcinoma | 3 | T2N0M0 | IB | Malignant | TC=30% |
10 | B2 | 60 | M | Lung | Squamous cell carcinoma | 2 | T2N0M0 | IB | Malignant | TC=25% |
11 | B3 | 54 | M | Lung | Squamous cell carcinoma | 2 | T2N2M0 | IIIA | Malignant | TC=30% |
12 | B4 | 69 | M | Lung | Squamous cell carcinoma | 2 | T2N0M0 | IB | Malignant | TC=80% |
13 | B5 | 57 | M | Lung | Squamous cell carcinoma | 3 | T2N0M0 | IB | Malignant | TC≥25% |
14 | B6 | 58 | M | Lung | Adenosquamous carcinoma | 3 | T2N0M0 | IB | Malignant | TC=25% |
15 | B7 | 46 | M | Lung | Adenosquamous carcinoma | 3 | T2N0M0 | IB | Malignant | TC=100% |
16 | B8 | 52 | M | Lung | Adenocarcinoma | 2--3 | T2N2M0 | IIIA | Malignant | TC≥25% |
17 | C1 | 62 | M | Lung | Adenocarcinoma | 2 | T1N0M0 | I | Malignant | TC≥25% |
18 | C2 | 70 | M | Lung | Adenocarcinoma | 3 | T2N0M0 | IB | Malignant | TC=85% |
19 | C3 | 50 | M | Lung | Adenocarcinoma | 3 | T2N0M0 | IB | Malignant | TC≥25% |
20 | C4 | 40 | M | Lung | Adenocarcinoma | 3 | T2N0M0 | IB | Malignant | TC≥25% |
21 | C5 | 65 | M | Lung | Squamous cell carcinoma | 2 | T2N0M0 | IB | Malignant | - |
22 | C6 | 35 | F | Lung | Squamous cell carcinoma | 2 | T2N0M0 | IB | Malignant | - |
23 | C7 | 63 | M | Lung | Squamous cell carcinoma | 2 | T2N0M0 | IB | Malignant | - |
24 | C8 | 52 | M | Lung | Squamous cell carcinoma | 2 | T2N0M0 | IB | Malignant | - |
25 | D1 | 65 | M | Lung | Squamous cell carcinoma | 2 | T2N0M0 | IB | Malignant | - |
26 | D2 | 69 | M | Lung | Squamous cell carcinoma | 2 | T3N1M0 | IIIA | Malignant | - |
27 | D3 | 54 | M | Lung | Squamous cell carcinoma | 2 | T2N0M0 | IB | Malignant | - |
28 | D4 | 54 | M | Lung | Squamous cell carcinoma | 2 | T2N0M0 | IB | Malignant | - |
29 | D5 | 36 | M | Lung | Squamous cell carcinoma | 2 | T2N0M0 | IB | Malignant | - |
30 | D6 | 48 | M | Lung | Squamous cell carcinoma | 2 | T2N0M0 | IB | Malignant | - |
31 | D7 | 27 | M | Lung | Squamous cell carcinoma | 2 | T2N0M0 | IB | Malignant | - |
32 | D8 | 64 | M | Lung | Squamous cell carcinoma | 2 | T2N2M0 | IIIA | Malignant | - |
33 | E1 | 64 | M | Lung | Squamous cell carcinoma | 2 | T2N0M0 | IB | Malignant | - |
34 | E2 | 46 | F | Lung | Squamous cell carcinoma | 2 | T2N0M0 | IB | Malignant | - |
35 | E3 | 58 | M | Lung | Squamous cell carcinoma | 2--3 | T2N0M0 | IB | Malignant | - |
36 | E4 | 62 | M | Lung | Squamous cell carcinoma | 3 | T3N1M0 | IIIA | Malignant | - |
37 | E5 | 57 | M | Lung | Squamous cell carcinoma | 3 | T2N0M0 | IB | Malignant | - |
38 | E6 | 58 | M | Lung | Squamous cell carcinoma | 3 | T2N0M0 | IB | Malignant | - |
39 | E7 | 58 | M | Lung | Squamous cell carcinoma | 3 | T3N2M0 | IIIA | Malignant | - |
40 | E8 | 48 | M | Lung | Squamous cell carcinoma | 3 | T2N0M0 | IB | Malignant | - |